\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Events

Cardiff Oncology will Present New Data from Lead Clinical Program in KRAS-mutated mCRC
 September 8, 2021
 1:00pm - 2:00pm PDT

Cardiff Oncology will present new data from its lead clinical program evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The upcoming virtual event will feature the clinical trial principal investigator, Heinz-Josef Lenz, M.D., FACP (USC Norris Comprehensive Cancer Center), and key clinical advisor Afsaneh Barzi, M.D., Ph.D., (City of Hope Comprehensive Cancer Center).

A Q&A session will follow the formal presentations.  

Please click on the link to replay the webcast: https://media.rampard.com/20210908/